Furthermore, miR-224 directly suppresses caspase-9 (CASP9) by targeting its mRNA, and knockdown of miR-224 in MDA-MB-231 cells significantly restores CASP9 protein levels, thereby inhibiting cell proliferation, migration, and invasion, suggesting preclinical drug candidate for breast cancer patients (Zhang et al., 2019). This evidence concerns the gene CASP9 and breast carcinoma.